CN101945872B - 作为mch拮抗剂的(1-吖嗪酮)-取代的吡啶并吲哚 - Google Patents

作为mch拮抗剂的(1-吖嗪酮)-取代的吡啶并吲哚 Download PDF

Info

Publication number
CN101945872B
CN101945872B CN200980105529.7A CN200980105529A CN101945872B CN 101945872 B CN101945872 B CN 101945872B CN 200980105529 A CN200980105529 A CN 200980105529A CN 101945872 B CN101945872 B CN 101945872B
Authority
CN
China
Prior art keywords
compound
methyl
pyrido
pyridin
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980105529.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101945872A (zh
Inventor
P·古佐
M·D·叙尔曼
A·J·亨德森
M·X·蒋
M·哈登
J·格拉鲍夫斯基
A·尤夏廷斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harmony Biotechnology Management Co
Original Assignee
Albany Molecular Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Research Inc filed Critical Albany Molecular Research Inc
Publication of CN101945872A publication Critical patent/CN101945872A/zh
Application granted granted Critical
Publication of CN101945872B publication Critical patent/CN101945872B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200980105529.7A 2008-01-11 2009-01-09 作为mch拮抗剂的(1-吖嗪酮)-取代的吡啶并吲哚 Active CN101945872B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2053008P 2008-01-11 2008-01-11
US61/020,530 2008-01-11
US4867708P 2008-04-29 2008-04-29
US61/048,677 2008-04-29
PCT/US2009/030646 WO2009089482A1 (en) 2008-01-11 2009-01-09 (1-azinone) -substituted pyridoindoles as mch antagonists

Publications (2)

Publication Number Publication Date
CN101945872A CN101945872A (zh) 2011-01-12
CN101945872B true CN101945872B (zh) 2014-07-23

Family

ID=40429805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980105529.7A Active CN101945872B (zh) 2008-01-11 2009-01-09 作为mch拮抗剂的(1-吖嗪酮)-取代的吡啶并吲哚

Country Status (13)

Country Link
US (4) US8716308B2 (enExample)
EP (2) EP2476680B1 (enExample)
JP (2) JP5501251B2 (enExample)
KR (1) KR101614723B1 (enExample)
CN (1) CN101945872B (enExample)
AU (1) AU2009204048B2 (enExample)
BR (1) BRPI0907122B8 (enExample)
CA (1) CA2727055C (enExample)
ES (1) ES2523580T3 (enExample)
IL (1) IL206594A (enExample)
MX (1) MX2010007430A (enExample)
NZ (1) NZ586120A (enExample)
WO (1) WO2009089482A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101614723B1 (ko) * 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
US9187455B2 (en) * 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
EP2802571A1 (en) * 2012-01-12 2014-11-19 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
HU230880B1 (hu) * 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
CN112739689B (zh) 2018-12-07 2022-06-03 优迈特株式会社 含氟嘧啶化合物及其制造方法
EP3937932B1 (en) * 2019-03-13 2025-01-08 The Rockefeller University Inhibitors of cgas for treating autoinflammatory diseases and cancer metastasis
EP4151210A3 (en) * 2020-01-10 2023-06-14 Harmony Biosciences, LLC Pyridine-carboline derivatives as mchr1 antagonists for use in therapy
JP7471407B2 (ja) 2020-05-19 2024-04-19 ユニマテック株式会社 含フッ素ピリミジン化合物および含フッ素ピリミジノン化合物
US12378229B2 (en) * 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
WO2023085142A1 (ja) 2021-11-12 2023-05-19 ユニマテック株式会社 含フッ素ピリミジン化合物、有害菌類防除剤および含フッ素ピリミジン化合物の製造方法
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3514462A (en) 1966-10-21 1970-05-26 Upjohn Co 1 and 2 ethoxy 3,4,5,10 - tetrahydroazepino(3,4-b) and (2,3-b)indoles and corresponding amino derivatives thereof
CH649553A5 (de) 1982-05-06 1985-05-31 Sandoz Ag Azepinoindole und verfahren zu deren herstellung.
DE3784594T2 (de) 1986-08-11 1994-01-05 Innovata Biomed Ltd Mikrokapseln enthaltende pharmazeutische Zusammensetzungen.
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
IT1223343B (it) 1987-11-03 1990-09-19 Also Lab Sas Formulazioni farmaceutiche per somministrazione transdermica
JPH0256485A (ja) 1988-04-27 1990-02-26 Glaxo Group Ltd ラクタム誘導体
HU207078B (en) 1988-08-02 1993-03-01 Glaxo Group Ltd Process for producing lactam derivatives and pharmaceutical compositions comprising such compounds
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
FI913899A7 (fi) 1989-02-23 1991-08-19 Rorer Int Holdings Inc Terapeuttiset aerosoliseokset
GB8904551D0 (en) 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
US4978669A (en) 1989-06-08 1990-12-18 Neurex Corporation Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives
US5169852A (en) 1989-06-08 1992-12-08 Neurex Corporation Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
CA2036337C (fr) 1990-02-15 2003-04-15 Francois Clemence Derives de la 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
US5225407A (en) 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5162336A (en) 1990-06-21 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists
US5187180A (en) 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
JP2951434B2 (ja) 1991-04-18 1999-09-20 三菱製紙株式会社 電子写真感光体
DE4130933A1 (de) 1991-09-13 1993-03-18 Schering Ag Neue (beta)-carbolinderivate, deren herstellung und verwendung in arzneimitteln
DE4240672A1 (de) 1992-11-24 1994-05-26 Schering Ag Neues Verfahren zur Herstellung von beta-Carbolinen
US5767131A (en) 1993-04-05 1998-06-16 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
IL109220A0 (en) 1993-04-05 1994-07-31 Synaptic Pharma Corp Dihydropyridines and new uses thereof
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
GB9418326D0 (en) 1994-09-12 1994-11-02 Lilly Industries Ltd Pharmaceutical compounds
JP3155008B2 (ja) 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
DE4436190A1 (de) 1994-10-10 1996-04-11 Gerhard Prof Dr Bringmann Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
AU3831495A (en) 1994-10-20 1996-05-15 American Home Products Corporation Indole derivatives useful as serotonergic agents
US5466688A (en) 1994-10-20 1995-11-14 American Home Products Corporation Pyrido[3,4-B]indole derivatives as serotonergic agents
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
HUP9801834A3 (en) 1995-10-12 2000-06-28 Supergen Inc Emeryville Liposome formulations of 5beta steroids
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
AU712082B2 (en) 1996-02-28 1999-10-28 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0912175A4 (en) 1996-06-28 1999-09-08 Merck & Co Inc FIBRINOGENIC RECEPTOR ANTAGONISTS
US5932582A (en) 1996-06-28 1999-08-03 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5811551A (en) 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
US6713645B1 (en) 1996-10-30 2004-03-30 Eli Lilly And Company Substituted tricyclics
CN1115342C (zh) 1998-03-17 2003-07-23 玛西夫公司 催眠性b一咔啉衍生物,它们的制备方法和作为医药产品的用途
ID23219A (id) 1998-04-17 2000-03-30 Lilly Co Eli Trisiklik tersubstitusi
JP2002535242A (ja) 1998-05-20 2002-10-22 ザ リポソーム カンパニー、インコーポレーテッド 新規な粒子状剤型
AU778735B2 (en) 1998-06-16 2004-12-16 Centre National De La Recherche Scientifique Fused azepinone cyclin dependent kinase inhibitors
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
CN1226290C (zh) 1998-12-14 2005-11-09 阿里根公司 新颖的核受体配体
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
EP1338272A1 (en) 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
KR100845769B1 (ko) 1999-02-03 2008-07-11 파우더젝트 리서치 리미티드 하이드로겔 입자 제제
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
JP2002538195A (ja) 1999-03-08 2002-11-12 パウダージェクト リサーチ リミテッド 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
WO2000062759A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Dry, mouldable drug formulation
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6485706B1 (en) 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
HK1043112A1 (zh) 1999-06-15 2002-09-06 Bristol-Myers Squibb Pharma Company 取代的稠杂环γ-咔啉
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2001013891A2 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
ATE267582T1 (de) 2000-01-20 2004-06-15 Basilea Pharmaceutica Ag Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
CO5261594A1 (es) 2000-03-02 2003-03-31 Smithkline Beecham Corp Inhibidores de myt1 cinasa
CA2402549A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
CA2406206C (en) 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
EP1286994A1 (en) 2000-05-15 2003-03-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6927223B1 (en) 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
AU2001268064A1 (en) 2000-06-07 2001-12-17 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
CA2412215A1 (en) 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
WO2002004456A1 (en) 2000-07-06 2002-01-17 Pharmacia & Upjohn Company SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES
AR035493A1 (es) 2000-09-20 2004-06-02 Upjohn Co Derivados de azepino (4,5b) indolina sustituidos, composicion farmaceutica y el uso de dichos derivados para preparar un medicamento
ATE302776T1 (de) 2000-10-02 2005-09-15 Lilly Icos Llc Kondensierte pyridoindolderivate
ATE332903T1 (de) 2000-10-03 2006-08-15 Lilly Icos Llc Kondensierte pyridoindolderivate
FI20002768L (fi) 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
EP1345898A2 (en) 2000-12-18 2003-09-24 Eli Lilly And Company Teracyclic carbazole derivates and their use as spla2 inhibitors
HUP0303432A3 (en) 2000-12-20 2012-09-28 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
WO2002059082A2 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
ES2272695T3 (es) 2001-02-12 2007-05-01 Lilly Icos Llc Derivados de carbolina.
WO2002064590A2 (en) 2001-02-12 2002-08-22 Lilly Icos Llc Carboline derivatives
GB0107106D0 (en) 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
CA2441792C (en) 2001-04-25 2010-08-03 Lilly Icos Llc Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
MXPA03011081A (es) 2001-06-05 2004-07-08 Lilly Icos Llc Derivados de carbolina como inhibidores de pde5.
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
US20030019437A1 (en) 2001-07-26 2003-01-30 John Fore Ungulate game animal feed system and method
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
WO2003014118A1 (en) 2001-08-08 2003-02-20 Pharmacia & Upjohn Company THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES
WO2003015750A1 (en) 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
JP2005507876A (ja) 2001-09-05 2005-03-24 ミナーバ バイオテクノロジーズ コーポレイション 癌を治療する組成物および方法
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
AU2003230689B2 (en) 2002-03-20 2006-06-29 Alkermes, Inc. Inhalable sustained therapeutic formulations
AU2003233118B8 (en) 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
US6906095B2 (en) 2002-05-10 2005-06-14 Wyeth Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6951881B2 (en) 2002-05-10 2005-10-04 Wyeth (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AU2003277215A1 (en) 2002-10-01 2004-04-23 Predix Pharmaceuticals Holdings, Inc. Novel neurokinin antagonists and methods of use thereof
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0305553D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Compounds
EP1462103A1 (en) 2003-03-25 2004-09-29 Faust Pharmaceuticals NO donors, combination products and uses as modulators of neurotransmitter release
WO2004103958A2 (en) 2003-05-19 2004-12-02 Michigan State University Preparation of hymenialdisine derivatives and use thereof
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
CN1798556A (zh) 2003-06-06 2006-07-05 麦克公司 作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚
US20060235012A1 (en) 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
WO2005012293A1 (ja) 2003-08-01 2005-02-10 Nippon Soda Co., Ltd. フェニルアゾール化合物、製造法および抗酸化薬
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2007518822A (ja) 2004-01-23 2007-07-12 カイロン コーポレイション 抗癌剤としてのテトラヒドロカルボリン化合物
CA2553670A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
US7994196B2 (en) 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US20050187387A1 (en) * 2004-02-25 2005-08-25 Lynch John K. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US7705017B2 (en) 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
ATE485715T1 (de) 2004-05-12 2010-11-15 Bayer Cropscience Ag Regulation des pflanzenwachstums
JP2008501628A (ja) 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
WO2006015035A1 (en) 2004-08-02 2006-02-09 Smithkline Beecham Corporation Useful compounds for hpv infection
DE102004039382A1 (de) 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2371811B1 (en) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
EP1831227B1 (en) 2004-12-17 2013-06-19 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
US20060167259A1 (en) 2005-01-21 2006-07-27 Cephalon, Inc. Direct racemization of indole derivatives
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
WO2006089874A1 (en) 2005-02-22 2006-08-31 Gpc Biotech Ag Benzo[2,3]azepino[4,5-b]indol-6-ones
DE102005016460A1 (de) 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
ATE542535T1 (de) 2005-05-04 2012-02-15 Develogen Ag Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
WO2006122931A1 (en) 2005-05-20 2006-11-23 Biovitrum Ab (Publ) Beta-carboline derivatives and theri use as ghsr modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
WO2009032123A2 (en) 2007-08-29 2009-03-12 Schering Corporation Tetracyclic indole derivatives and their use for treating or preventing viral infections
PL1910338T3 (pl) 2005-07-14 2011-02-28 Irm Llc Związki heterotetracykliczne jako mimetyki TPO
US20070027178A1 (en) 2005-07-28 2007-02-01 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists
CA2619276A1 (en) 2005-08-12 2007-02-22 Genentech, Inc. Pentacyclic kinase inhibitors
EP1757607A1 (en) 2005-08-24 2007-02-28 Molisa GmbH N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases
CA2619770A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
AU2006292429A1 (en) 2005-09-16 2007-03-29 Serenex, Inc. Carbazole derivatives
CA2623026A1 (en) 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents
US20070149557A1 (en) 2005-11-21 2007-06-28 Amgen Inc. CXCR3 antagonists
AU2006325815B2 (en) 2005-12-15 2012-07-05 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AU2006342024A1 (en) 2005-12-16 2007-10-25 Genentech, Inc. Tetracyclic kinase inhibitors
EP1966164B1 (en) 2005-12-21 2013-03-06 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
WO2007124288A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of cdc7
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20080124319A1 (en) 2006-05-16 2008-05-29 Charalabos Pothoulakis Methods for treating inflammation by disrupting MCH-mediated signaling
HRP20110917T1 (hr) 2006-05-19 2012-03-31 Abbott Laboratories Derivati azabicikličkih alkana supstituirani fuzioniranim bicikloheterociklima aktivni u središnjem živčanom sustavu
PE20080150A1 (es) * 2006-06-02 2008-04-11 Janssen Pharmaceutica Nv Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
WO2007142217A1 (ja) * 2006-06-07 2007-12-13 Banyu Pharmaceutical Co., Ltd. １－フェニルピリドン誘導体
CN101074207B (zh) 2006-06-08 2014-03-26 中国科学院成都有机化学有限公司 一类水溶性的手性二胺衍生物及其应用和制备
CN101108859A (zh) 2006-07-17 2008-01-23 上海恒瑞医药有限公司 长春碱类化合物、其制备方法及其在医药上的用途
RU2317989C1 (ru) 2006-08-24 2008-02-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ АЗЕПИНО[4,3-b]ИНДОЛЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CA2657183A1 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
WO2008046155A1 (en) 2006-10-20 2008-04-24 Dia-B Tech Limited Methods for regulating glucose homeostasis and agents therefor
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
ES2483866T3 (es) 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
WO2008081282A2 (en) 2006-12-20 2008-07-10 Glenmark Pharmaceuticals S.A. Process for the synthesis of n9-(3,5-dichloro-4-pyridyl)-6- difluoromethoxybenzo(4,5)furo(3,2-c)pyridine-9-carboxamide and salts thereof
JP2010515745A (ja) 2007-01-10 2010-05-13 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−フロピリジノン置換インダゾール
KR20090101370A (ko) 2007-01-10 2009-09-25 알바니 몰레큘라 리써치, 인크. 5-피리디논 치환된 인다졸
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
DE102007009319A1 (de) 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009235A1 (de) 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US8063089B2 (en) 2007-02-28 2011-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of nucleophosmin (NPM) and methods for inducing apoptosis
KR101805914B1 (ko) 2007-03-12 2017-12-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
US20090214529A9 (en) 2007-05-22 2009-08-27 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
US20110002855A1 (en) 2007-06-25 2011-01-06 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
CA2689945A1 (en) 2007-06-26 2008-12-31 Astrazeneca Ab 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors
ES2382982T3 (es) 2007-07-21 2012-06-15 Albany Molecular Research, Inc. Indazoles sustituidos con 5-piridinona y composiciones farmacéuticas de los mismos
WO2009022104A1 (en) 2007-08-13 2009-02-19 De Montfort University Fascaplysin derivatives and their use in the treatment of cancer
CA2597193A1 (en) 2007-08-13 2009-02-13 De Montfort University Compounds and uses
US11202775B2 (en) 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
KR101614723B1 (ko) * 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof

Also Published As

Publication number Publication date
ES2523580T3 (es) 2014-11-27
JP2011509937A (ja) 2011-03-31
BRPI0907122B8 (pt) 2021-05-25
IL206594A (en) 2015-05-31
US20170204095A1 (en) 2017-07-20
CA2727055A1 (en) 2009-07-16
US20160159798A1 (en) 2016-06-09
AU2009204048A1 (en) 2009-07-16
EP2476680A1 (en) 2012-07-18
MX2010007430A (es) 2010-12-21
WO2009089482A1 (en) 2009-07-16
US8716308B2 (en) 2014-05-06
KR20100124251A (ko) 2010-11-26
CA2727055C (en) 2016-12-20
US20100331339A9 (en) 2010-12-30
JP2014129417A (ja) 2014-07-10
EP2476680B1 (en) 2014-08-27
JP5501251B2 (ja) 2014-05-21
AU2009204048B2 (en) 2013-08-01
BRPI0907122B1 (pt) 2019-04-16
US9650378B2 (en) 2017-05-16
KR101614723B1 (ko) 2016-04-22
US20090275590A1 (en) 2009-11-05
US20140206696A1 (en) 2014-07-24
NZ586120A (en) 2012-07-27
US9296743B2 (en) 2016-03-29
CN101945872A (zh) 2011-01-12
BRPI0907122A2 (pt) 2015-07-14
IL206594A0 (en) 2010-12-30
EP2240481A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
CN101945872B (zh) 作为mch拮抗剂的(1-吖嗪酮)-取代的吡啶并吲哚
US12304915B2 (en) SOS1 inhibitors
US11390609B2 (en) Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN104619709B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN116589467A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶（btk）及其使用方法
CN113316576A (zh) 用于治疗癌症的作为HPK1抑制剂的2,3-二氢-1H-吡咯并[3,4-c]吡啶-1-酮衍生物
CN108699038A (zh) 作为Rock抑制剂的螺环庚烷水杨酸酰胺和相关化合物
AU2008279321B2 (en) 5-pyridinone substituted indazoles
CN107295798A (zh) 苯并氮杂*二甲酰胺化合物
CN107873031A (zh) 作为tnf活性调节剂的苯并噁嗪酮衍生物及其类似物
WO2022199662A1 (zh) 一种多环化合物及其应用
CN116981675A (zh) 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
WO2006059164A2 (en) Pyrrolopyridine-2-carboxylic acid amides
US20240238425A1 (en) HSD17B13 Inhibitors and/or Degraders
HK1169111A (en) (1-azinone)-substituted pyridoindoles
JP2024504824A (ja) 芳香族複素環化合物及びその製造方法と用途
HK40053093A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Hadden Mark

Inventor after: Guzzo Peter

Inventor after: Henderson Alan John

Inventor after: M.X.Jiang

Inventor after: M. Harden

Inventor after: Grabowski James

Inventor after: A.YORXIYASKI

Inventor before: Hadden Mark

Inventor before: Guzzo Peter

Inventor before: Henderson Alan John

Inventor before: M.X.Jiang

Inventor before: M. Harden

Inventor before: Grabowski James

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: PETER GUZZO DAVID SURMAN MATTHEW JOHN HENDERSON ALAN XIAOWU JIANG MAY MARK HADDEN JAMES GRABOWSKI TO: PETER GUZZO DAVID SURMAN MATTHEW JOHN HENDERSON ALAN XIAOWU JIANG MAY MARK HADDEN JAMES GRABOWSKI USYATINSKY ALEXANDER

C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: New York, United States

Patentee after: Kuria Global Ltd.

Country or region after: U.S.A.

Address before: New York, United States

Patentee before: ALBANY MOLECULAR RESEARCH, Inc.

Country or region before: U.S.A.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250122

Address after: Pennsylvania, USA

Patentee after: Harmony Biotechnology Co.,Ltd.

Country or region after: U.S.A.

Address before: New York, United States

Patentee before: Kuria Global Ltd.

Country or region before: U.S.A.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250207

Address after: Pennsylvania, USA

Patentee after: Harmony Biotechnology Management Co.

Country or region after: U.S.A.

Address before: Pennsylvania, USA

Patentee before: Harmony Biotechnology Co.,Ltd.

Country or region before: U.S.A.